Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus

Type 2 diabetes mellitus (T2DM) can increase the risk of several common cancers, including breast cancer (BC). The purpose of the present study was to investigate the clinicopathological features and prognosis of BC patients with or without T2DM. Seventy-eight patients were diagnosed with T2DM prior...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Mol Clin Oncol
المؤلفون الرئيسيون: HE, DE, BAI, JING-WEN, LIU, JING, DU, CAI-WEN, HUANG, WEN-HE, ZHANG, GUO-JUN
التنسيق: Artigo
اللغة:Inglês
منشور في: D.A. Spandidos 2015
الموضوعات:
Articles
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4471586/
https://ncbi.nlm.nih.gov/pubmed/26137275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2015.522
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
id pubmed-4471586
record_format dspace
spelling pubmed-44715862015-07-01 Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus HE, DE BAI, JING-WEN LIU, JING DU, CAI-WEN HUANG, WEN-HE ZHANG, GUO-JUN Mol Clin Oncol Articles Type 2 diabetes mellitus (T2DM) can increase the risk of several common cancers, including breast cancer (BC). The purpose of the present study was to investigate the clinicopathological features and prognosis of BC patients with or without T2DM. Seventy-eight patients were diagnosed with T2DM prior to the diagnosis of BC in the Cancer Hospital of Shantou University Medical College (Shantou, China) between 2002 and 2008. A total of 300 BC patients without T2DM were randomly selected as study controls during the same period. The clinicopathological characteristics, overall survival (OS) and disease-free survival (DFS) rates of these two groups were compared. Fifty-five BC patients and 133 control patients with T2DM were >50 years old (70.5 and 44.3%, respectively). There were more T2DM BC patients with body mass index (BMI) ≥25 kg/m(2) (46.2 vs. 23.3%) and these patients had a higher rate of lymph node involvement (67.9 vs. 55.0%). The DFS of the two groups was 32.1 vs. 22.3%. The OS of the two groups was 24.4 vs. 13.7%. Following adjustment for BMI, tumor-node metastasis stage and stratification of age, the relapse risk of T2DM BC patients was >2-fold higher than that of the control group in the estrogen receptor/progesterone receptor (ER/PR)-positive patients. In Her-2-negative BC patients, the relapse risk of T2DM patients was 2.237-fold higher than that of the non-T2DM patients. In conclusion, T2DM BC patients were significantly older and more likely to be overweight, and had more lymph nodes involvement. T2DM was associated with poor prognosis in ER/PR positive or Her-2-negative BC patients. D.A. Spandidos 2015-05 2015-03-02 /pmc/articles/PMC4471586/ /pubmed/26137275 http://dx.doi.org/10.3892/mco.2015.522 Text en Copyright © 2015, Spandidos Publications
institution US NLM
collection PubMed Central
language Inglês
format Artigo
topic Articles
spellingShingle Articles
HE, DE
BAI, JING-WEN
LIU, JING
DU, CAI-WEN
HUANG, WEN-HE
ZHANG, GUO-JUN
Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus
description Type 2 diabetes mellitus (T2DM) can increase the risk of several common cancers, including breast cancer (BC). The purpose of the present study was to investigate the clinicopathological features and prognosis of BC patients with or without T2DM. Seventy-eight patients were diagnosed with T2DM prior to the diagnosis of BC in the Cancer Hospital of Shantou University Medical College (Shantou, China) between 2002 and 2008. A total of 300 BC patients without T2DM were randomly selected as study controls during the same period. The clinicopathological characteristics, overall survival (OS) and disease-free survival (DFS) rates of these two groups were compared. Fifty-five BC patients and 133 control patients with T2DM were >50 years old (70.5 and 44.3%, respectively). There were more T2DM BC patients with body mass index (BMI) ≥25 kg/m(2) (46.2 vs. 23.3%) and these patients had a higher rate of lymph node involvement (67.9 vs. 55.0%). The DFS of the two groups was 32.1 vs. 22.3%. The OS of the two groups was 24.4 vs. 13.7%. Following adjustment for BMI, tumor-node metastasis stage and stratification of age, the relapse risk of T2DM BC patients was >2-fold higher than that of the control group in the estrogen receptor/progesterone receptor (ER/PR)-positive patients. In Her-2-negative BC patients, the relapse risk of T2DM patients was 2.237-fold higher than that of the non-T2DM patients. In conclusion, T2DM BC patients were significantly older and more likely to be overweight, and had more lymph nodes involvement. T2DM was associated with poor prognosis in ER/PR positive or Her-2-negative BC patients.
author HE, DE
BAI, JING-WEN
LIU, JING
DU, CAI-WEN
HUANG, WEN-HE
ZHANG, GUO-JUN
author_facet HE, DE
BAI, JING-WEN
LIU, JING
DU, CAI-WEN
HUANG, WEN-HE
ZHANG, GUO-JUN
author_sort HE, DE
title Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus
title_short Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus
title_full Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus
title_fullStr Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus
title_full_unstemmed Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus
title_sort clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus
publisher D.A. Spandidos
container_title Mol Clin Oncol
publishDate 2015
url https://ncbi.nlm.nih.gov/pmc/articles/PMC4471586/
https://ncbi.nlm.nih.gov/pubmed/26137275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2015.522
_version_ 1807729982723588096

مواد مشابهة